Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridinilazole vs Vancomycin in Adolescents with C. difficile Infection
NCT04802837Phase 3Terminated
- Sponsor
- Summit Therapeutics
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ridinilazole in Clostridioides difficile infection (CDI), sponsored by Summit Therapeutics. Started May 2021; status: terminated.
02
Drugs
ridinilazole
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04802837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802837.